High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort.
기술보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
892 subjects was considered for inclusion in this study, and 1133 volunteers were finally selected, including 600 healthy controls, 160 patients diagnosed with other diseases of urinary system, 89 patients diagnosed with benign prostate hyperplasia (BPH), and 284 PCa patients.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] This study demonstrated the clinical potential of an LDI-MS-based non-invasive urine biopsy for early prostate cancer detection, particularly in improving diagnostic accuracy for patients with tPSA levels in the gray zone (3–10 ng/mL). [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s40364-025-00804-z.
[BACKGROUND] Prostate cancer (PCa) remains a leading global malignancy, yet current diagnostic reliance on prostate-specific antigen (PSA) testing is limited by suboptimal sensitivity and specificity
APA
Jiang X, Zhang C, et al. (2025). High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort.. Biomarker research, 13(1), 94. https://doi.org/10.1186/s40364-025-00804-z
MLA
Jiang X, et al.. "High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort.." Biomarker research, vol. 13, no. 1, 2025, pp. 94.
PMID
40629411 ↗
Abstract 한글 요약
[BACKGROUND] Prostate cancer (PCa) remains a leading global malignancy, yet current diagnostic reliance on prostate-specific antigen (PSA) testing is limited by suboptimal sensitivity and specificity for early-stage detection. The present study aims to establish an effective high-throughput screening technique for accurate PCa diagnosis.
[METHODS] A large-scale cohort of 28,892 subjects was considered for inclusion in this study, and 1133 volunteers were finally selected, including 600 healthy controls, 160 patients diagnosed with other diseases of urinary system, 89 patients diagnosed with benign prostate hyperplasia (BPH), and 284 PCa patients. Discovery and internal validation phases of diagnostic models were conducted through machine learning of urine metabolic fingerprints obtained by laser desorption/ionization mass spectrometry (LDI-MS). Furthermore, the developed diagnostic model was verified in an external validation cohort.
[RESULTS] In retrospective cohort, the stepwise binary classification model achieved satisfactory diagnostic performance with areas under curves (AUCs) of 0.9599–0.9957 in the discovery ( = 567) and internal validation dataset ( = 284). In the external validation cohort ( = 282), AUC values from the ROC curves that differentiate Non-PD from PD, BPH from PCa, and HC from UD were 0.9815, 0.9705, and 0.9980, respectively. More than 95% significant PCa patients in the gray area (3 < tPSA < 10 ng/mL) were successfully identified from BPH subjects. Notably, four metabolite-related candidate genes were identified in this work, including , , and .
[CONCLUSIONS] This study demonstrated the clinical potential of an LDI-MS-based non-invasive urine biopsy for early prostate cancer detection, particularly in improving diagnostic accuracy for patients with tPSA levels in the gray zone (3–10 ng/mL).
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s40364-025-00804-z.
[METHODS] A large-scale cohort of 28,892 subjects was considered for inclusion in this study, and 1133 volunteers were finally selected, including 600 healthy controls, 160 patients diagnosed with other diseases of urinary system, 89 patients diagnosed with benign prostate hyperplasia (BPH), and 284 PCa patients. Discovery and internal validation phases of diagnostic models were conducted through machine learning of urine metabolic fingerprints obtained by laser desorption/ionization mass spectrometry (LDI-MS). Furthermore, the developed diagnostic model was verified in an external validation cohort.
[RESULTS] In retrospective cohort, the stepwise binary classification model achieved satisfactory diagnostic performance with areas under curves (AUCs) of 0.9599–0.9957 in the discovery ( = 567) and internal validation dataset ( = 284). In the external validation cohort ( = 282), AUC values from the ROC curves that differentiate Non-PD from PD, BPH from PCa, and HC from UD were 0.9815, 0.9705, and 0.9980, respectively. More than 95% significant PCa patients in the gray area (3 < tPSA < 10 ng/mL) were successfully identified from BPH subjects. Notably, four metabolite-related candidate genes were identified in this work, including , , and .
[CONCLUSIONS] This study demonstrated the clinical potential of an LDI-MS-based non-invasive urine biopsy for early prostate cancer detection, particularly in improving diagnostic accuracy for patients with tPSA levels in the gray zone (3–10 ng/mL).
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s40364-025-00804-z.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- FASN at the crossroads of tumor metabolism, immune evasion, and therapy resistance: Mechanistic insights and therapeutic opportunities.
- Association of gastroesophageal reflux disease with the incidence of multiple cancers: a systematic review and meta-analysis.
- Single-cell RNA sequencing and spatial transcriptomic analysis reveal a distinct population of G6PD cells with aberrant bile acid metabolism in hepatocellular carcinoma.
- ASO Visual Abstract: Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer-Development and Validation of a Clinical-Inflammatory Nomogram.
- miRNA-HK2 networks in cancer metabolism: Mechanisms and dual-targeting therapeutic opportunities.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.
- LCMS-Net: Deep Learning for Raw High Resolution Mass Spectrometry Data Applied to Forensic Cause-of-Death Screening.
- Hidden findings: How often does Holmium laser enucleation of the prostate (HoLEP) uncover prostate cancer?
- An exploratory serum metabolomics study for screening and staging of breast cancer.
- The emerging role of mA methylation in prostate-related diseases: mechanisms and clinical implications.
- Deciphering the multifarious biomedicinal properties of marine-derived Streptomyces kunmingensis through In vitro, In silico and GC-MS-based metabolomic approaches.